Trinity Biotech (NASDAQ:TRIB – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Thursday.
Trinity Biotech Stock Up 1.6 %
Shares of TRIB opened at $0.69 on Thursday. Trinity Biotech has a fifty-two week low of $0.63 and a fifty-two week high of $3.55. The firm’s 50 day moving average price is $0.83 and its 200 day moving average price is $1.24. The company has a market cap of $12.48 million, a P/E ratio of -0.31 and a beta of 1.20.
Institutional Trading of Trinity Biotech
An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC grew its holdings in shares of Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 5.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 378,590 shares of the company’s stock after buying an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 78.97% of the stock is owned by institutional investors.
Trinity Biotech Company Profile
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
See Also
- Five stocks we like better than Trinity Biotech
- Canada Bond Market Holiday: How to Invest and Trade
- Is Myers Industries Poised for a Breakout?
- 3 Stocks to Consider Buying in October
- Is BigBear.ai’s 25% Plunge a False Alarm or Fire Sale?
- The Most Important Warren Buffett Stock for Investors: His Own
- Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
